Novartis Plumps For Share Buybacks Before Bolt-On M&A
$15bn Allocated For Scheme
Executive Summary
The Basel-headquartered giant has decided to spend a major chunk of its $20.7bn windfall from the sale of its stake in Roche on a stock repurchasing program up to the end of 2023, disappointing some observers who wanted to see big licensing deals or acquisitions.
You may also be interested in...
Novartis Bets On Buybacks Due To Limited M&A Options
Chief financial officer Harry Kirsch has told reporters that decent bolt-on acquisition opportunities are rare and in their absence, buybacks represent a sensible use of capital.
No Cash Boost For Novartis From Sandoz Spin-Off
After a lengthy review, Novartis has confirmed Sandoz will be a publicly traded standalone company listed on the SIX Swiss Exchange, although CEO Vas Narasimhan says he will still consider bids for the division.
The Top Five (Non-COVID) Pharma Stories Of 2021
The emergence and rapid spread of the Omicron variant has kept COVID-19 firmly in the headlines but the biopharma industry has had plenty on its plate on top of tackling the pandemic. Scrip has taken a look back at five of the biggest non-COVID-19 story themes of 2021 in no particular order.